Direct compression tableting is selected after the crystalline fraction of Dixomethopamine veterinary grade API has been passed through a 0.5 mm safety screen to remove agglomerates and, where necessary, a pin mill to narrow the particle-size distribution. The material is dry-blended with milled lactose monohydrate and microcrystalline cellulose in a 600 L bin blender at 12 rpm for 20 minutes; the final blending step with magnesium stearate is limited to 3 minutes to avoid over-lubrication. In a tablet core with a total mass of 400 mg and a label claim of 20 mg, the API addition ratio is 5.0% w/w, while the excipient split is typically 30–45% w/w microcrystalline cellulose, 20–35% w/w lactose monohydrate, 2–4% w/w crospovidone, and 0.5–1.0% w/w magnesium stearate. The blend is compressed on a rotary tablet press at 25–60 rpm with precompression force 8–12 kN and main compression force 15–20 kN; ejection force is logged continuously and a sustained increase beyond the validated range is treated as a batch-hold event. In-process testing includes average mass per Ph. Eur. 2.9.5, disintegration time per Ph. Eur. 2.9.1, and content uniformity per Ph. Eur. 2.9.40 or USP <905>. Film coating with an aqueous dispersion at 3–5% w/w weight gain is applied in a side-vented coating pan at a product temperature of 38–42°C. This route is limited by moisture: if ambient relative humidity exceeds 60%, granulated material is pre-dried to a loss-on-drying endpoint below 2.0% per USP <731> and tableting is conducted in conditioned air at 20–25°C and 35–45% RH to reduce picking and capping. The terminal product forms are uncoated oral tablets, scored tablets, chewable tablets, and film-coated tablets packed into aluminium-PVC blisters or HDPE containers. Residual solvent compliance is handled through VICH GL18, and the API release certificate is reviewed against the harmonised pharmacopoeial monograph for residual solvent classes before batch start.

What Changes When Dixomethopamine Is Processed into a Terminally Sterilized Injectable?

The injectable route eliminates the particle-flow requirements of tablet compression but introduces the constraints of filter compatibility, endotoxin control, and hydrolytic stability. The API is initially dissolved in water for injection at 20–25°C with pH adjustment using dilute hydrochloric acid or sodium hydroxide; if the dose is 50 mg/mL, the API input is 5.0% w/v before normalisation for assay. The solution is clarified through a 0.45 μm membrane and then sterilised through a 0.22 μm sterilising-grade filter; terminal sterilisation at 121°C for 15 minutes is used only when stability data support an F₀ ≥ 8 requirement per Ph. Eur. 5.1.1. The fill line operates in an EU GMP Annex 1 Grade A environment with Grade B background; aseptic filling uses peristaltic pump dosing into Type I borosilicate vials. The finished product is tested for sterility per Ph. Eur. 2.6.1 and USP <71>, with bacterial endotoxins per Ph. Eur. 2.6.14 and USP <85>. The addition ratio is defined by the labelled concentration; for a 100 mL multi-dose vial containing 100 mg active, the content is 1.0 mg/mL or 0.1% w/v. Multi-dose vials require preservation efficacy testing per Ph. Eur. 5.1.3 unless the formulation is self-preserving. Nitrogen blanketing is applied when oxygen-sensitive degradation products are observed, and vial headspace oxygen is maintained below 2.0% v/v during sealing. The terminal finished product types are single-dose vials, multi-dose vials, and pre-filled syringes for veterinary use.

The oral drinking-water powder segment uses a water-dispersible carrier such as lactose monohydrate or sorbitol to distribute the API at a defined concentration in farm water tanks. A representative sachet delivers 500 mg active in a 20 g fill if the label claim is 500 mg per sachet, so the API addition ratio is 2.5% w/w. The blend is manufactured in a ribbon blender with working volume not exceeding 70% of shell capacity, mixed for 15–20 minutes, and screened through a 0.5 mm sieve before packaging. Blend uniformity is assessed by sampling at 10 points and accepting a relative standard deviation ≤ 5.0% with individual values within ±10.0% of mean assay. The powder must pass Ph. Eur. 2.9.5 for mass uniformity and water content measurement per USP <921>; sachets are sealed with aluminium-foil laminate at a heat-seal strength of ≥ 6 N/15 mm tested per a manufacturer’s internal method. At farm level, the powder is reconstituted at rates between 0.5 g/L and 5.0 g/L depending on the dosing regimen; the terminal equipment is a 1000 L drinking-water tank with recirculation to avoid sedimentation. The finished product types are unit-dose sachets, metering pail jars, and water-dispersible powder sachets for pigs and poultry. The operational boundary is particle size: if the API is milled below 75 μm and contains more than 10% fines, static adhesion to packaging surfaces may reduce label-claim recovery; pre-drying at RH below 60% is required before blending.

When Medicated Premix Is Diluted in Compound Feed at the Feed Mill

A premix is an intermediate formulation rather than a final dosage form; the API is first mixed into a carrier at a fixed concentration, then diluted in feed at the farm or feed mill. Under EU Regulation 2019/4, medicated feed must be produced in approved establishments, and the homogeneity of the active substance must be documented. A 5.0% w/w premix is typically diluted at 1:200 to achieve a final feed concentration of 0.25 g/kg, but the actual dilution factor is determined by the veterinarian’s prescription and the target species. The process includes stepwise geometric dilution in a horizontal ribbon mixer, using a carrier such as ground wheat bran or calcium carbonate with moisture below 12.0% w/w; batch-to-batch coefficient of variation after 10 minutes of mixing must remain below 5.0%. The premix is then either packed into 25 kg bags or incorporated into pelleted feed through a pellet mill where conditioning temperature is kept at 70–85°C and steam pressure at 2.0–3.5 bar, depending on product stability data. The finished product types are 5.0% and 10.0% w/w premixes, medicated meal, and medicated pellets. Compliance references include 21 CFR 558 for approved feed-use drugs where applicable in the United States and national withdrawal-period tables under veterinary prescribing records. If the API is sensitive to pelleting temperature, the premix may be top-dressed onto the finished feed to avoid thermal exposure.

Capsule filling of Dixomethopamine-containing powder blends requires a particle-size distribution narrow enough to maintain consistent fill weight across a dosator or tamping-pin machine. In a representative hard gelatin capsule with total fill mass 350 mg and active content 40 mg, the API addition ratio is 11.4% w/w. The remaining fill is composed of lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate at 0.5% w/w. The powder is blended in a V-blender at 60–75% capacity, sampled at 10 locations, and checked for assay RSD ≤ 5.0%. The filling machine operates at 40,000–80,000 capsules per hour using compression dosators with pin diameter 9.0 mm; fill weight is controlled by depth adjustment and vacuum. Capsules are checked for average mass per Ph. Eur. 2.9.5, disintegration per Ph. Eur. 2.9.1 and USP <701>, and uniformity of content per Ph. Eur. 2.9.40 and USP <905>. Metal detection at 0.5 mm ferrous and non-ferrous threshold is installed after the empty capsule orientation station. The terminal products are hard gelatin and hydroxypropyl methylcellulose capsules in PVC-PVDC blister or HDPE bottles. A processing constraint is that the lubricant must not exceed 1.0% w/w; higher levels can reduce capsule dissolution and affect bioavailability. Published data for this specific configuration is limited, so the blend is bracketed by a design-of-experiments program across fill weight and compression force before commercial release.

Oral Solution Co-solvency Limits and Preservation Requirements

The solution dosage form uses a defined solvent system, usually purified water with propylene glycol or glycerol as co-solvent, to keep the API fully dissolved at the labelled concentration. If the label concentration is 20 mg/mL, the API addition ratio is 2.0% w/v; the co-solvent fraction is adjusted so that the API remains dissolved after 24 hours at 5°C, and the pH is maintained within the range of 4.0–5.5 using a citrate or phosphate buffer. The process consists of dissolving the API in the co-solvent under nitrogen, adding purified water, adjusting pH under a calibrated pH meter, filtering through a 0.45 μm or 0.22 μm filter, and filling into amber glass or PET bottles. The fill volume is checked per the registered specification; pH is tested per Ph. Eur. 2.2.3. Antimicrobial preservation is a critical quality attribute because oral solutions can be exposed to repeated opening; the container-closure system must pass Ph. Eur. 5.1.3 and USP <51> criteria. The product is packed with a volumetric dosing pump calibrated to deliver ±5.0% of the labelled dose. Finished product types are veterinary oral solutions, pump bottles, and unit-dose polyethylene vials. The main process boundary is oxygen exposure: if oxygen-sensitive, nitrogen sparging and headspace oxygen below 2.0% v/v are required; if the API is light-sensitive, amber glass providing ultraviolet protection per USP <660> is used.

Granulation for Sachets, Bolus Tablets and Metered-Dose Delivery Systems

Granulation is not a separate clinical application but a downstream processing route selected when the API is fine, poorly flowing, or requires density modification for metering devices. The API is typically dry-mixed with a diluent and binder at a concentration between 10.0% and 30.0% w/w, depending on final sachet or bolus mass; for a 5 g sachet carrying 500 mg active, the addition ratio is 10.0% w/w. The granulation process uses a top-spray fluid-bed granulator with inlet air temperature 55–65°C, spray rate 20–40 g/min, and atomisation air pressure 1.0–2.0 bar; binder solution such as pregelatinised starch or polyvinylpyrrolidone is sprayed until granules achieve a loss-on-drying of 1.0–2.5% per USP <731>. The granules are milled through 0.8 mm or 1.0 mm screens and tested for bulk density, tapped density, and particle-size distribution above 250 μm; the reproducibility of the granulation endpoint is confirmed by near-infrared moisture sensors. Terminal finished products include granules for oral paste, sachet granules, and compressed boluses with hardness controlled at 80–120 N. The route includes an unavoidable quality target: if the granulation end-point tolerance exceeds ±0.5% loss-on-drying, the compression profile shifts; therefore in-process loss-on-drying is monitored at 5-minute intervals. The applicable standards are Ph. Eur. 2.9.5 for mass uniformity, Ph. Eur. 2.9.40 for content uniformity, and USP <905> as a harmonised alternative. The process cannot be used with superdisintegrant levels above 5.0% because over-granulation reduces tablet disintegration to beyond Ph. Eur. 2.9.1 limits.